This page uses content from Wikipedia and is licensed under CC BY-SA.

AB-005

AB-005
AB-005.png
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
ChEMBL
Chemical and physical data
FormulaC23H32N2O
Molar mass352.522 g·mol−1
3D model (JSmol)

AB-005 or [1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)-methanone is a designer drug offered by online vendors as a cannabimimetic agent. The structure and pharmacological activity of AB-005 was published in 2010, prior to its commercial availability in 2012, where it was reported to have high affinity for both CB1 (Ki = 5.5 nM) and CB2 receptors (Ki = 0.48 nM).[1] AB-005 features groups found in other previously reported synthetic cannabinoids: the tetramethylcyclopropane group of UR-144 and XLR-11 as well as the (1-methyl-2-piperidinyl)methyl substituent of AM-1248 and AM-1220. No information regarding the in vivo activity of AB-005 has been published, and only anecdotal reports are known of its psychoactivity in humans.

Legal status

In 2013, psychoactive products in New Zealand containing this drug were given interim approval under psychoactive substances legislation.[2]

See also

References

  1. ^ Frost, J. M.; et al. (2010). "Indol-3-ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB2 Cannabinoid Receptor Activity". Journal of Medicinal Chemistry. 53 (1): 295–315. doi:10.1021/jm901214q. PMID 19921781.
  2. ^ "Interim Product Approvals". Ministry of Health,. Archived from the original on 21 August 2013. Retrieved 2 January 2013.CS1 maint: extra punctuation (link)